CD1a x CD3ε BTCE

CD1a x CD3ε BTCE is a novel asymmetric (2+1 format) bispecific T-cell engager (BTCE) protein therapeutic. It is designed with a bivalent arm targeting CD1a (found on cortical T-cell acute lymphoblastic leukemia [T-ALL] cells) and a monovalent arm targeting CD3ε (present on T cells). CD1a x CD3ε BTCE binds both the tumor antigen CD1a and the T-cell antigen CD3ε, redirecting T-cell cytotoxicity selectively to CD1a-expressing T-ALL cells while minimizing off-tumor effects and fratricide. The CD1a-binding domain was developed from the UMG2 monoclonal antibody, which recognizes a unique CD1a epitope that is absent on normal T lymphocytes, enabling tumor-selective targeting. In preclinical models, the drug demonstrated potent in vitro and in vivo activity against human CD1a+ T-ALL, leading to significant tumor inhibition and improved survival in animal models. It is under preclinical or early clinical development for the treatment of cortical-derived T-ALL[1][2][3].

Other names

anti-CD1a x anti-CD3 bispecific T-cell engageranti-CD-1a x anti-CD3 bispecific T-cell engageranti-CD 1a x anti-CD3 bispecific T-cell engagerCD1a x CD3 BTCECD-1a x CD3 BTCECD 1a x CD3 BTCE